X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SCI-210 a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated for the treatment of Autism Spectrum Disorder in children between 5 and 18 years.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
SCI- 210 consisits of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA (palmitoylethanolamide). It is being developed for the treatment of Autism Spectrum Disorder.
Lead Product(s): Palmitoylethanolamide,Cannabidiol
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
SCI-210 (cannabidiol) is a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated in clinical trials for the treatment of autism spectrum disorder.
Lead Product(s): Cannabidiol,Cannamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: SCI-210
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Lead Product(s): Cannabidiol,Cannamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinson's disease.
Lead Product(s): 3-Methylmethcathinone,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Lead Product(s): Cannabidiol,Cannamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Negev Autism Center Soroka University Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
